Janux Therapeutics CMO departs without cause

Janux Therapeutics, Inc. reported that its Chief Medical Officer, William Go, M.D., Ph.D., departed the company on June 23, 2026.

Rhea-AI Filing Summary

Janux Therapeutics, Inc. reported that its Chief Medical Officer, William Go, M.D., Ph.D., departed the company on June 23, 2026. The departure was treated as a termination without “Cause” under Janux’s Change in Control and Severance Benefit Plan.

The company has begun searching for a new Chief Medical Officer. Until a successor is appointed, existing clinical leaders will collectively handle the responsibilities. Janux stated that this transition does not change its development strategy, regulatory plans, or previously disclosed clinical timelines, and that Dr. Go’s departure did not stem from any disagreement over operations, policies, or practices.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

CMO departure date: June 23, 2026 Change in Control and Severance Benefit Plan reference: Exhibit 10.12 Commission File Number: 001-40475

3 metrics

CMO departure date June 23, 2026 Date William Go, M.D., Ph.D. departed as Chief Medical Officer

Change in Control and Severance Benefit Plan reference Exhibit 10.12 Plan filed with Registration Statement on Form S-1

Commission File Number 001-40475 Janux Therapeutics SEC registration reference

Key Terms

Chief Medical Officer, termination without “Cause”, Change in Control and Severance Benefit Plan, clinical timelines

4 terms

Chief Medical Officer financial

"William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc."

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

termination without “Cause” financial

"departed ... under circumstances that the Company determined to constitute a termination without “Cause”"

Change in Control and Severance Benefit Plan financial

"under the terms of the Company’s Change in Control and Severance Benefit Plan"

clinical timelines financial

"The transition does not affect the Company's development strategy, regulatory plans, or previously disclosed clinical timelines."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Janux Therapeutics (JANX) disclose in this 8-K?

Janux Therapeutics disclosed that its Chief Medical Officer, William Go, M.D., Ph.D., departed the company on June 23, 2026. His exit is classified as a termination without “Cause” under the company’s Change in Control and Severance Benefit Plan.

Was the Janux Therapeutics (JANX) CMO departure related to any disagreement?

The company stated Dr. Go’s departure was not due to any disagreement regarding Janux Therapeutics’ operations, policies, or practices. This indicates the change is described as a personnel transition rather than a dispute over strategy or governance matters.

How will Janux Therapeutics (JANX) manage clinical responsibilities after the CMO exit?

Janux Therapeutics said its existing clinical leadership team will assume responsibilities previously overseen by Chief Medical Officer William Go. These leaders will manage clinical activities while the company conducts a search for a permanent successor to fill the CMO role.

Does the Janux Therapeutics (JANX) CMO departure affect development strategy or timelines?

Janux reported that the transition does not affect its development strategy, regulatory plans, or previously disclosed clinical timelines. The company emphasizes continuity in its clinical and regulatory programs despite this senior leadership change in the Chief Medical Officer position.

What severance framework applies to the Janux Therapeutics (JANX) CMO departure?

The company determined Dr. Go’s departure constitutes a termination without “Cause” under its Change in Control and Severance Benefit Plan. That plan, previously filed with the SEC, governs severance-related terms for qualifying executive terminations at Janux Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:05 PM Learn about SEC filing dates

false000181771300018177132026-06-232026-06-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2026

Janux Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-40475	82-2289112
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
10955 Vista Sorrento Parkway, Suite 200 San Diego, California		92130
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 751-4493

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		JANX		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 23, 2026, William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. (the "Company") under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Company’s Change in Control and Severance Benefit Plan (a copy of which is filed as Exhibit 10.12 to the Company's Registration Statement on Form S-1 (File No. 333-256297), filed with the Securities and Exchange Commission on May 19, 2021). The Company has initiated a search for his successor. In the interim, responsibilities previously overseen by Dr. Go will be assumed by members of the Company's existing clinical leadership team. The transition does not affect the Company's development strategy, regulatory plans, or previously disclosed clinical timelines. Dr. Go's departure was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		JANUX THERAPEUTICS, INC.
Date: June 23, 2026		By:	/s/ David Campbell, Ph.D.
			David Campbell, Ph.D.
			President and Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 26.6 KB